The existence of chronic Lyme disease is an issue of sharp debate within the medical community. Some healthcare workers who call themselves "Lyme literate" insist that chronic Lyme disease is frequently diagnosed and treated by primary care physicians. Others, however, including the American Academy of Pediatrics and the Infectious Diseases Society of America, state that there is no convincing biological evidence that chronic Lyme disease exists. Many doctors are concerned with the potential dangers associated with the prolonged and intensive use of oral and intravenous antibiotics (the recommended treatment for chronic Lyme disease), such as blood clots and life threatening infections. A study soon to be published in the Journal of Pediatrics attempts to determine how often chronic Lyme disease is actually being diagnosed and treated.
Named for a community in Connecticut where it was first diagnosed, Lyme disease is a multi-system infection caused by the bacteria B. burgdoferi. Treatment typically includes a 10-28 day course of oral antibiotics. "Lyme literate" groups, such as the International Lyme and Associated Diseases Society (ILADS), define chronic Lyme disease as a debilitating illness caused by a persistent infection of B. burgdoferi; symptoms include fatigue, difficulty concentrating, headaches, and irritability. Treatment requires oral and/or intravenous antibiotic therapy that can last from several months to several years.
Dr. Michael Johnson, now at the Hospital of Saint Raphael in New Haven, and Dr. Henry Feder, of the University of Connecticut Health Center, attempted to determine how frequently Connecticut doctors were diagnosing and treating chronic Lyme disease. Of the 285 primary care physicians who responded to the survey, nearly one-half did not believe that chronic Lyme disease is a legitimate diagnosis, and 48 percent were undecided. Only six physiciansor 2.1 percentdiagnosed and treated patients for chronic Lyme disease. These 6 physicians treated patients for an average of 20 weeks with oral antibiotics; however, because these six physicians did not treat their patients with months to years of oral and/or intravenous antibiotics, they do not fit into the "Lyme literate" category.
Contrary to the assertions of the "Lyme literate" community, Feder does not believe intravenous antibiotic treatment is common practice. "The 6 physicians in our study who treated patients with chronic Lyme disease do not fit into the 'Lyme literate' group," he explains, "because they treated their patients for an average of 20 weeksnot months to yearsand it does not appear that intravenous therapy was used." According to Feder, "Physicians who diagnose patients with chronic Lyme disease, and put these patients in harm's way with months to years of potentially dangerous antibiotics, are outliers." These findings call into question the claims of "Lyme literate" advocacy groups, like ILADS, that chronic Lyme disease is frequently diagnosed and treated by many primary care physicians.
Although the number of physicians diagnosing and treating patients with chronic Lyme disease may be small, their influence seems to be growing. "The 'Lyme literate' network has been pivotal in advocating legislation in multiple states requiring insurance companies to cover the costs of intravenous therapy for presumed chronic Lyme disease," Feder notes. The debate over chronic Lyme disease is likely to continue as insurance companies and legislative bodies become more involved.
The study, reported in "Chronic Lyme Disease: A Survey of Connecticut Primary Care Physicians" by Michael Johnson, MD and Henry Feder, Jr. MD, appears in The Journal of Pediatrics, DOI 10.1016/j.jpeds.2010.06.031, published by Elsevier.
Stay prepared and protected with Infection Control Today's newsletter, delivering essential updates, best practices, and expert insights for infection preventionists.
From Pandemic to Endemic: How the Protective Face Mask Market Is Evolving
August 2nd 2025Once a symbol of crisis, face masks have evolved into everyday essentials—driven not only by pandemic preparedness but by rising air pollution, cultural shifts, and workplace safety regulations. As innovation and demand grow worldwide, the protective face mask market is poised for long-term expansion well beyond COVID-19.
Sharps Safety Starts with Us: Why Infection Preventionists Must Lead the Charge
August 2nd 2025Sharps injuries remain a silent but serious threat in health care that infection preventionists are uniquely equipped to confront. With underreporting widespread and safety devices underused, it’s time for IPs to step into a leadership role, using their expertise in systems thinking, education, and policy to build a culture where staff protection is as prioritized as patient care.
The Green Revolution in SPD: From Hidden Cost to Frontline Change
August 2nd 2025As climate change accelerates, health care’s environmental impact faces increased scrutiny, with sterile processing departments (SPDs) emerging as key change agents. Often behind the scenes, SPD professionals can lead sustainability by turning routine practices into ecofriendly protocols that protect both patient and planetary health.